The Cooper Companies, Inc. (COO) Stock Analysis 2026

HealthcareMedical Instruments & Supplies
$57.94
as of 2026-10-16
-17.7% (52-week)50D MA $72.48  |  200D MA $73.43

BriMind AI Score

Proprietary
37
Weak
Price CAGR
2.0%
1Y Return
-20.5%
Analyst Upside
+49.9%
Rev Growth
7.9%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$56.74-2.1% potential
Bear Case
$46.77
Bull Case
$77.76
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($47.69) and Wall Street's consensus target ($65.80).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

COO Revenue & Profitability Breakdown

This chart shows how COO's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$4.23B
Cost of Revenue
-$1.46B
Gross Profit
$2.77B65.6% margin
Operating Expenses
-$2.77B
Operating Income
$0-2.9% margin
Net Income
$235.8M5.6% margin
Gross Margin
65.6%
Operating Margin
-2.9%
Net Margin
5.6%

Key Financial Metrics

The Cooper Companies, Inc. trades at a trailing P/E of 60.31x, generates $424.3M in free cash flow, runs a debt/equity ratio of 33.09, and converts shareholder equity into profit at a 2.9% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$13.88B
P/E (Trailing)
60.31
P/E (Forward)
14.25
PEG Ratio
0.67
Revenue
$4.23B
Revenue Growth
7.9%
Earnings Growth
26.9%
Gross Margin
65.6%
Operating Margin
-2.9%
Net Margin
5.6%
Return on Equity
2.9%
Return on Assets
2.5%
Free Cash Flow
$424.3M
Debt / Equity
33.09
Current Ratio
1.27
Quick Ratio
0.53
Beta
0.82
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
0.6%
Inst. Ownership
109.2%
Short % Float
4.5%
Book Value / Share
$42.27

Wall Street Analyst Consensus

Wall Street analysts covering The Cooper Companies, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $81.50 (+40.7% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$81.50+40.7% upside

Technical Price Signals

COO is currently in a death cross pattern, trading below its 50-day average of $72.48 and below its 200-day average of $73.43. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$57.94
50-Day MA
$72.48
▼ Price below
200-Day MA
$73.43
▼ Price below
Death Cross Pattern
Price below both MAs — bearish signal

More Healthcare Stock Analysis

In-depth reports on companies operating alongside COO — business models, bull and bear cases, and the metrics that matter.

ISRGIntuitive Surgical, Inc.Medical Instruments & SuppliesNVSTEnvista Holdings CorporationMedical Instruments & SuppliesALGNAlign Technology, Inc.Medical Instruments & SuppliesUNHUnitedHealth Group IncorporatedHealthcare PlansVEEVVeeva Systems Inc.Health Information ServicesMRNAModerna, Inc.BiotechnologyLLYEli Lilly and CompanyDrug Manufacturers - GeneralEWEdwards Lifesciences CorporationMedical Devices

Unlock the Full COO Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis